Jordan Kho, PhD

#medicalaffairs #geneticist 🧬 #genetherapy #scientist 🔬

[Jordan Kho, PhD @JKhoPhD]

Celebrating the 25th year anniversary of the Brendan Lee Lab during ASHG Annual Meeting in DC. It’s great catching up with some of my old colleagues!

[Jordan Kho, PhD @JKhoPhD]

Mechanistically, I think the most interesting finding of our study is that nitric oxide deficiency in ASLD led to imbalance of claudins (downregulation of claudin-5 and upregulation of claudin-1). This is a phenomenon also observed during BBB leakage in chronic stroke.

[Jordan Kho, PhD @JKhoPhD]

The research that I conducted during my postdoc at @bcmgenetics is finally published! This study was partially funded by the grant that I received from the @UCDConsortium and dedicated to the memory of Cindy Lemons from the National Urea Cycle Disorder Foundations.

[JCI insight @JCI_insight]

Argininosuccinate lyase deficiency-associated NO reduction underlies BBB dysfunction: https://t.co/1ULuPvByJo
@JKhoPhD @bcmgenetics
#Genetics #Neuroscience

[Jordan Kho, PhD @JKhoPhD]

We discover that argininosuccinate lyase deficiency (ASLD) may cause blood-brain barrier breakdown, providing a novel mechanism on the pathogenesis of neurocognitive deficits in patients with ASLD (beyond hyperammonemia).

[Agios @AgiosPharma]

We're proud to announce the Phase 2 portion of the global RISE UP study in #sicklecelldisease met its primary endpoint of hemoglobin response. These results support proceeding with Phase 3. Read more about this exciting progression for patients here: https://t.co/YQjeLqntF2

[Agios @AgiosPharma]

We’re excited to announce the launch of our new Agios Medical Twitter account for U.S. HCPs! If you’re a healthcare provider based in the U.S., please follow along for updates on our latest hemolytic anemia research and resources. https://t.co/1VCdrZYINw

[STAT @statnews]

We finally have new drugs for sickle cell disease. Why are so few patients taking them? https://t.co/OW2bMrUQ1C

[ASH @ASH_hematology]

ASH has adopted the term "classical hematology," in place of what was formerly referred to as "benign" or "nonmalignant." Discoveries within #classicalheme have significantly advanced the field & continue to better the lives of those living with non-cancerous blood disorders.
1/2

[Jordan Kho, PhD @JKhoPhD]

Rather enjoy attending the last day of #ASH22 when things are less busy/chaotic and I can focus less on work-related talks. But my first in-person ASH congress has been an awesome experience.

[Jordan Kho, PhD @JKhoPhD]

@CaptainAV It was nice meeting you in person!

[Jordan Kho, PhD @JKhoPhD]

Had the honor of attending the very first conference specifically dedicated to #pyruvatekinasedeficiency today. Listening to rare disease patients’ stories always inspires me and reminds me why I love what I do. #60yearspkd

[Agios @AgiosPharma]

During last week’s @SCDAAorg event, we unveiled a music video created by Blaze and DeMitrious dedicated to their fellow #sicklecellwarriors who demonstrate incredible resilience and rise above the challenges of living with #sicklecelldisease. Watch here: https://t.co/IaKkoeOZLM

[Jordan Kho, PhD @JKhoPhD]

Today is #WorldSickleCellDay. I’m grateful for the opportunity to attend my first #FSCDR Symposium last weekend to not only learn more about sickle cell disease but also meet amazing Sickle Cell Warriors! It’s also nice to attend a conference in-person again!

[Agios @AgiosPharma]

We're proud to announce that data from the pivotal Phase 3 ACTIVATE study of PYRUKYND ® (mitapivat) were published on April 14, 2022 in the New England Journal of Medicine. Read more and see the link to the publication in the announcement below! https://t.co/jbalhQdrWH

[Agios @AgiosPharma]

Coming soon: We're joining the fight against #SickleCell and stand alongside the #SickleCellWarrior community.

[Jordan Kho, PhD @JKhoPhD]

After working virtually for almost a year, it feels nice that I finally got to see my teammates in-person this week in Cambridge, MA. #bestteamever #MedicalAffairs.

[Jordan Kho, PhD @JKhoPhD]

Celebrating #InternationalMSLDay with fellow Houston-based MSLs! #MedicalAffairs

[Jordan Kho, PhD @JKhoPhD]

#ShowYourStripes #RareDiseaseDay

[National Organization for Rare Disorders (NORD) @RareDiseases]

Today is Rare Disease Day! 🦓

It's time to Show Your Stripes! How are you getting involved? Why is this day important to you? Share you answer on social media using the hashtags #RareDiseaseDay and #ShowYourStripes.

Learn more at: https://t.co/p0g5CEy1W0

[Jordan Kho, PhD @JKhoPhD]

Proud to say that I’ve worked directly with 4 of these outstanding investigators!

[Rare Diseases Clinical Research Network @rarediseasesnet]

Driving Discoveries in #UreaCycleDisorders ➡️ Learn more about the current work & future goals of @UCDConsortium early investigators: https://t.co/SOTDRHL41w

#RDDNIH #RareDiseaseDay #RDCRN

[Jordan Kho, PhD @JKhoPhD]

First disease-modifying therapy for hemolytic anemia in adults with Pyruvate Kinase Deficiency! Honored that I get to be part of the launch team! #RareDisease #pyruvatekinasedeficiency

[Agios @AgiosPharma]

We're so excited to share that the FDA approved our first #GeneticallyDefinedDisease medication – the first therapy for a serious, rare blood disorder. We have studied this medication for 7+ years in the clinic & are proud to deliver it to patients today! https://t.co/I1Be7oWwiT